Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Since the emergence of the coronavirus disease 19 (COVID-19), a number of studies have reported the presence of cardiovascular diseases in affected patients and linked them with a higher risk of mortality. We conducted an online search in Medline/PubMed to identify original cohorts comparing data between survivors and non-survivors from COVID-19. The presence of cardiovascular events and related biomarkers were compared between the 2 groups. Data on 1,845 hospitalized patients with COVID-19 were pooled from 12 comparative studies. The overall mortality rate in relation to COVID-19 was 17.6%. Men aged > 50 years old were more likely to die from COVID-19. Significant co-morbidities contributing to mortality were hypertension, diabetes mellitus, smoking, a previous history of cardiovascular disease including chronic heart failure, and cerebrovascular accidents. A significant relationship was observed between mortality and patient presentation with dyspnea, fatigue, tachycardia, and hypoxemia. Cardiovascular disease-related laboratory biomarkers related to mortality were elevated serum level of lactate dehydrogenase, creatine kinase, brain natriuretic peptide, and cardiac troponin I. Adverse cardiovascular disease-related clinical events preceding death were shock, arrhythmias, and acute myocardial injury. In conclusion, severe clinical presentation and elevated biomarkers in COVID-19 patients with established risk factors can predict mortality from cardiovascular causes. Published by Elsevier Inc. (Am J Cardiol 2020;135:50–61)

Methods

A systematic review was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)6 and performed in compliance with the Meta-analyses Of Observational Studies in Epidemiology Checklist.7 Two independent researchers performed the literature review, screened the articles, and obtained the full text of the eligible studies.

An electronic search was performed in Medline/PubMed to identify studies with original data on mortality in patients with COVID-19. A combination of the following keywords was used: “COVID-19” or “SARS-CoV-2” or “SARS CoV-2” or “2019 novel coronavirus” or “2019-nCoV” and “mortality” or “death” or “died” or “die”. Due to a high volume of preprint publication on this topic, we limited our online database search to the Medline/PubMed. The title and abstract of articles were screened for relevancy and the full text of relevant studies was reviewed for eligibility.

Original studies in adult patients with COVID-19 comparing the demographics, clinical characteristics, radiologic findings, or laboratory parameters between survivors and non-survivors were eligible for inclusion if available in English language full-text. Eligible articles were included into meta-analysis if data on variables of interest were extractable in crude numbers for both the survivor and non-survivor groups. Case report, review articles, modeling studies, and commentaries were excluded.

The main end point of this systematic review was to compare cardiovascular disease risk factors, its manifestations, and related laboratory parameters between COVID-19 survivors and non-survivors. Cardiovascular disease risk factors included gender, hypertension, dyslipidemia, diabetes, and a previous history of cardiovascular disease, including heart failure and cerebrovascular events. Clinical presentations pertinent to the cardiovascular system included shortness of breath, tachycardia, and other vital signs.
instability. The cardiovascular disease-related laboratory biomarkers included cardiac troponin I (CTnI), brain natriuretic peptide (BNP) or proBNP, lactate dehydrogenase (LDH), and creatine kinase (CK).

Review Manager (RevMan. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used to perform meta-analysis of the extracted data in this systematic review. Data on variables of interest was extracted from at least 2 eligible studies to perform the quantitative analysis. An odds ratio (OR) was calculated as the prevalence of a potential risk factor in the non-survivor group compared with the survivor group. A mean difference (MD) was a weighted difference in the mean of a continuous variable between the 2 groups. If enough data was available, the laboratory parameters were analyzed both as a continuous variable, that is, their average serum levels, and as a categorical variable, that is, the reported value as elevated or positive. Mantel-Haenszel statistical method was applied using a random-effects analysis model. Statistical significance was set at p < 0.05.

Results

Figure 1 shows the PRISMA flowchart of our systematic literature review, article screening, and study selection.

A total of 12 studies were included encompassing 3,257 hospitalized patients with COVID-19 who either died from the SARS-CoV-2 infection, discharged from the hospital, or continued to remain under observation between December 20, 2019 and March 15, 2020.\textsuperscript{3–19} Death from COVID-19 occurred in 574 patients, whereas 1,271 patients survived and were discharged from the hospital (Table 1). These 1,845 patients constituted the population of our meta-analysis. The mortality rate ranged from 11.3%\textsuperscript{19} to 61.5%\textsuperscript{16} with a pooled average of 17.6%.

Meta-analysis of data showed that non-survivors were generally men (OR= 2.1, p < 0.0001), aged > 50 years (OR 8.7, p <0.00001), with established comorbidities including hyperlipidemia (OR = 44.1, p = 0.0005), smoking (OR = 13.5, p = 0.0009), hypertension (OR = 2.6, p < 0.00001), and diabetes mellitus (OR = 1.7, p = 0.03). Non-survivors had a history of chronic cardiovascular disease (OR = 2.7, p = 0.0004), including chronic heart failure (OR = 27.8, p < 0.0001) or cerebrovascular disease (OR = 4.4, p = <0.00001), and a respiratory condition (OR = 3.4, p = 0.006) (Table 2 and Figure 2).

In terms of clinical presentation at admission, presence of hypoxemia (MD = –12 % hemoglobin saturation, p < 0.00001), a higher heart rate (MD = 5.4 beats/minute, p = 0.04), dyspnea (OR = 4.8, p <0.0001), and fatigue (OR = 1.4, p = 0.04) were associated with death from COVID-19 (Table 2).

Mortality from COVID-19 was preceded by acute respiratory distress syndrome (OR = 122.0, p < 0.0001), circulatory shock (OR = 53.1, p = 0.001), arrhythmias (OR = 22.4, p = 0.02), and acute cardiac injury (OR = 20.0, p <0.0001) (Table 2 and Figure 2).
Mortality from COVID-19 infection was associated with elevation of cardiovascular disease-related laboratory biomarkers such as cardiac troponin I (OR = 25.5, \( p < 0.0001 \)), LDH (OR = 11.8, \( p = 0.03 \)), and CK (OR = 2.3, \( p = 0.04 \)) (Table 2 and Figure 2). Additionally, serum level of BNP or pro-BNP was significantly elevated in the non-survivor group compared to the survivor group.

A meta-analysis was also performed on available data for 4 major therapeutic modalities provided to COVID-19 patients. These included antiviral treatment, antibiotics, corticosteroid administration, and mechanical ventilation. Of these, corticosteroid administration (OR = 3.3, \( p = 0.001 \)) and mechanical ventilation (OR = 9.07, \( p = 0.02 \)) were used more commonly in non-survivors than in survivors (Figure 3).

| First Author (Reference #) | City     | Sample Size | Date of Last Discharge | Mortality Rate |
|----------------------------|----------|-------------|------------------------|----------------|
| 1  Cao (8)                 | Wuhan    | 102         | 02/15/2020             | 16.7 %         |
| 2  Chen (9)                | Wuhan    | 799         | 02/28/2020             | 14.1 %         |
| 3  Chen (10)               | Wuhan    | 203         | 02/20/2020             | 12.8 %         |
| 4  Deng (19)               | Wuhan    | 964         | 02/21/2020             | 11.3 %         |
| 5  Du (11)                 | Wuhan    | 179         | N/A                    | 11.7 %         |
| 6  Li (12)                 | Wuhan    | 25          | 03/05/2020             | 20 %           |
| 7  Tang (13)               | Wuhan    | 183         | 02/13/2020             | 11.5 %         |
| 8  Wang (14)               | Wuhan    | 339         | 03/05/2020             | 19.2 %         |
| 9  Yan (15)                | Wuhan    | 193         | N/A                    | 56 %           |
| 10 Yang (16)               | Wuhan    | 52          | 02/09/2020             | 61.5 %         |
| 11 Yuan (17)               | Wuhan    | 27          | N/A                    | 37 %           |
| 12 Zhou (18)               | Wuhan    | 191         | N/A                    | 28.3%          |

All studies were published in 2020. N/A = Not available.

Table 2
Factors associated with mortality from COVID-19 in the meta-analysis of comparative studies

| Variable                        | OR [95% CI]     | Heterogeneity (I^2) | \( p \)  |
|---------------------------------|-----------------|---------------------|---------|
| Age > 50 years                  | 8.7 [5.1, 14.9] | 0%                  | <0.00001|
| Men                             | 2.1 [1.5, 2.7]  | 30%                 | <0.00001|
| Hyperlipidemia                  | 44.1 [5.2, 374.4]| 0%                  | 0.0005  |
| Chronic heart failure           | 27.8 [6.3, 122.9]| 0%                  | <0.0001 |
| Current smoker                  | 13.5 [2.9, 63.5]| 75%                 | 0.0009  |
| Chronic respiratory diseases    | 3.4 [1.4, 8.1]  | 43%                 | 0.006   |
| Any cardiovascular diseases     | 2.7 [1.6, 4.8]  | 29%                 | 0.0004  |
| Hypertension                    | 2.6 [1.9, 3.7]  | 39%                 | <0.00001|
| Diabetes                        | 1.7 [1.0, 2.8]  | 47%                 | 0.03    |
| Heart rate at admission, mean difference in beats/minute | 5.3 [0.2, 10.5] | 58% | 0.04 |
| Dyspnea                         | 4.8 [2.4, 9.7]  | 74%                 | <0.0001 |
| Partial arterial O2 pressure to the fraction of inspired O2 at admission, mean difference in PaO2:FiO2 | −54.9 [−87.9, −22.0] | 76% | 0.001 |
| Transcutaneous pulse oximetry, mean difference in % hemoglobin saturation | −12.00 [−12.5, −11.5] | 0% | <0.00001 |
| Brain natriuretic peptide or pro-brain natriuretic peptide, mean difference in pg/ml | 721.7 [657.0, 786.4] | 0% | <0.00001 |
| Lactate dehydrogenase, mean difference in U/L | 214.1 [133.9, 294.4] | 98% | <0.00001 |
| Creatine kinase, mean difference in U/L | 56.1 [11.2, 101.1] | 97% | 0.01 |
| Cardiac troponin I, mean difference in pg/ml | 18.7 [−3.4, 40.8] | 99% | 0.10 |
| Elevated serum level of cardiac troponin I | 25.5 [7.2, 90.7] | 44% | <0.00001 |
| Elevated level of lactate dehydrogenase | 11.8 [1.3, 105.8] | 90% | 0.03 |
| Elevated level of creatine kinase | 2.3 [1.04, 5.1] | 2% | 0.04 |
| Acute respiratory distress syndrome | 122.01 [69.96, 212.79] | 0% | <0.00001 |
| Shock                           | 53.10 [4.67, 603.89] | 85% | 0.001 |
| Arrhythmia                      | 22.4 [1.8, 283.6] | 90% | 0.02 |
| Acute myocardial injury         | 20.3 [7.8, 53.3] | 71% | <0.00001 |
| Acute heart failure             | 3.2 [0.3, 30.1]  | 89% | 0.3    |

Variables are presented as odds ratio, unless mentioned otherwise, i.e. mean difference.
Figure 2. Forest plots demonstrating pooled analysis of cardiovascular system involvement in patients with COVID-19. The meta-analysis estimated a mean difference and 95% confidence interval for the continuous variables and an odds ratio and 95% confidence interval for the categorical variables. Mantel-Haenszel statistical method using a random-effects model was utilized for all of the analysis.
### Comorbidity: Hypertension

| Study or Subgroup | Non survivors Events | Survivors Events | Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|----------------------|------------------|-------|--------|--------------------------------|--------------------------------|
| Cao (8)           | 11                   | 17               | 54    | 11     | 3.73 [2.20, 5.48]              |                                |
| Chen (10)         | 9                    | 19               | 117   | 9      | 1.60 [0.50, 5.61]              |                                |
| Chen (9)          | 54                   | 113              | 167   | 54     | 2.86 [1.71, 4.80]              |                                |
| Deng (11)         | 40                   | 109              | 149   | 40     | 3.16 [1.67, 5.96]              |                                |
| Du (11)           | 13                   | 21               | 34    | 13     | 4.80 [1.56, 10.51]             |                                |
| Li (12)           | 1                    | 5                | 6     | 1      | 4.75 [0.24, 92.97]             |                                |
| Tang (13)         | 0                    | 21               | 21    | 0      | Not estimable                  |                                |
| Wang (14)         | 32                   | 65               | 97    | 32     | 1.54 [0.69, 2.59]              |                                |
| Yan (15)          | 39                   | 108              | 147   | 39     | 2.44 [1.25, 4.77]              |                                |
| Yang (16)         | 0                    | 32               | 32    | 0      | Not estimable                  |                                |
| Yuan (17)         | 6                    | 10               | 16    | 6      | 50.56 [2.38, 1075.32]          |                                |
| Zhou (18)         | 17                   | 54               | 71    | 17     | 1.51 [0.75, 3.03]              |                                |

Total (95% CI) 574 1271 100.0% 2.62 [1.86, 3.67]

Heterogeneity: Tau² = 0.10; Ch² = 14.64, df = 9 (P = 0.10); I² = 30%
Test for overall effect: Z = 5.58 (P = 0.00001)

### Comorbidity: Diabetes

| Study or Subgroup | Non survivors Events | Survivors Events | Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|----------------------|------------------|-------|--------|--------------------------------|--------------------------------|
| Cao (8)           | 6                    | 17               | 23    | 6      | 8.73 [2.20, 33.48]             |                                |
| Chen (10)         | 5                    | 19               | 24    | 5      | 1.48 [0.40, 5.61]              |                                |
| Chen (9)          | 24                   | 113              | 137   | 24     | 1.62 [0.66, 3.94]              |                                |
| Deng (11)         | 17                   | 109              | 126   | 17     | 2.20 [0.93, 5.16]              |                                |
| Du (11)           | 6                    | 21               | 27    | 6      | 1.94 [0.69, 5.45]              |                                |
| Li (12)           | 1                    | 5                | 6     | 1      | 13.67 [0.49, 393.18]           |                                |
| Tang (13)         | 0                    | 21               | 21    | 0      | Not estimable                  |                                |
| Wang (14)         | 11                   | 65               | 76    | 11     | 1.09 [0.53, 2.26]              |                                |
| Yan (15)          | 11                   | 108              | 119   | 11     | 0.96 [0.38, 2.43]              |                                |
| Yang (16)         | 7                    | 32               | 39    | 7      | 2.52 [0.47, 13.58]             |                                |
| Yuan (17)         | 0                    | 10               | 10    | 0      | Not estimable                  |                                |
| Zhou (18)         | 0                    | 54               | 54    | 0      | 0.06 [0.00, 0.94]              |                                |

Total (95% CI) 574 1271 100.0% 1.70 [1.04, 2.78]

Heterogeneity: Tau² = 0.26; Ch² = 16.99, df = 9 (P = 0.05); I² = 47%
Test for overall effect: Z = 2.12 (P = 0.03)

### Comorbidity: Hyperlipidemia

| Study or Subgroup | Non survivors Events | Survivors Events | Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|----------------------|------------------|-------|--------|--------------------------------|--------------------------------|
| Cao (8)           | 0                    | 17               | 17    | 0      | Not estimable                  |                                |
| Chen (10)         | 0                    | 19               | 19    | 0      | Not estimable                  |                                |
| Chen (9)          | 0                    | 113              | 113   | 0      | Not estimable                  |                                |
| Deng (11)         | 0                    | 109              | 109   | 0      | Not estimable                  |                                |
| Du (11)           | 1                    | 21               | 22    | 1      | 43.8% [2.91, 588.42]           |                                |
| Li (12)           | 0                    | 5                | 5     | 0      | Not estimable                  |                                |
| Tang (13)         | 0                    | 21               | 21    | 0      | Not estimable                  |                                |
| Wang (14)         | 0                    | 65               | 65    | 0      | Not estimable                  |                                |
| Yan (15)          | 10                   | 88               | 98    | 10     | Not estimable                  |                                |
| Yang (16)         | 0                    | 32               | 32    | 0      | Not estimable                  |                                |
| Yuan (17)         | 0                    | 10               | 10    | 0      | Not estimable                  |                                |
| Zhou (18)         | 11                   | 54               | 65    | 11     | 56.2% [4.20, 1259.20]          |                                |

Total (95% CI) 574 1271 100.0% 44.10 [5.19, 374.41]

Heterogeneity: Tau² = 0.00; Ch² = 0.32, df = 1 (P = 0.57); I² = 0%
Test for overall effect: Z = 3.47 (P = 0.0005)

Figure 2. Continued
Comorbidity: Cardiovascular diseases

| Study | Non survivors | Survivors | Total | Weight | Odds Ratio | M-H, Random, 95% CI |
|-------|---------------|-----------|-------|--------|------------|-------------------|
| Cao (9) | 3 | 17 | 2 | 85 | 7.3% | 8.99 [1.36, 59.08] |
| Chen (10) | 6 | 19 | 5 | 36 | 12.2% | 2.06 [0.74, 11.06] |
| Chen (9) | 16 | 113 | 7 | 161 | 19.7% | 3.63 [1.44, 9.14] |
| Deng (19) | 13 | 109 | 4 | 116 | 15.1% | 3.79 [1.20, 12.01] |
| Du (11) | 0 | 21 | 0 | 158 | Not estimable | |
| Li (12) | 1 | 5 | 3 | 20 | 4.4% | 1.42 [0.11, 17.46] |
| Tang (13) | 0 | 21 | 0 | 162 | Not estimable | |
| Wang (14) | 21 | 65 | 32 | 274 | 27.4% | 3.61 [1.91, 6.83] |
| Yan (15) | 0 | 108 | 4 | 85 | 3.3% | 0.08 [0.00, 1.57] |
| Yang (16) | 3 | 32 | 2 | 20 | 7.3% | 0.93 [0.14, 6.12] |
| Yuan (17) | 0 | 10 | 0 | 17 | Not estimable | |
| Zhou (18) | 0 | 54 | 2 | 137 | 3.1% | 0.50 [0.02, 10.53] |

Total (95% CI) | 574 | 1271 | 100.0% | 2.72 [1.56, 4.76] |

Heterogeneity: Tau² = 0.19; Ch² = 11.26, df = 8 (P = 0.19); I² = 29%
Test for overall effect: Z = 3.51 (P = 0.0004)

Comorbidity: Chronic heart failure.

| Study | Non survivors | Survivors | Total | Weight | Odds Ratio | M-H, Random, 95% CI |
|-------|---------------|-----------|-------|--------|------------|-------------------|
| Cao (9) | 0 | 17 | 0 | 85 | Not estimable | |
| Chen (10) | 0 | 19 | 0 | 38 | Not estimable | |
| Chen (9) | 1 | 113 | 0 | 161 | 21.5% | 4.31 [0.17, 108.66] |
| Deng (19) | 0 | 109 | 0 | 116 | Not estimable | |
| Du (11) | 0 | 21 | 0 | 158 | Not estimable | |
| Li (12) | 0 | 5 | 0 | 20 | Not estimable | |
| Tang (13) | 0 | 21 | 0 | 162 | Not estimable | |
| Wang (14) | 0 | 65 | 0 | 274 | Not estimable | |
| Yan (15) | 27 | 108 | 0 | 85 | 27.9% | 57.70 [3.46, 961.55] |
| Yang (16) | 0 | 32 | 0 | 20 | Not estimable | |
| Yuan (17) | 3 | 10 | 0 | 17 | 23.2% | 16.33 [0.75, 356.86] |
| Zhou (18) | 13 | 54 | 0 | 137 | 27.3% | 89.46 [5.21, 1537.18] |

Total (95% CI) | 574 | 1271 | 100.0% | 27.79 [6.28, 122.95] |

Heterogeneity: Tau² = 0.00; Ch² = 2.48, df = 3 (P = 0.48); I² = 0%
Test for overall effect: Z = 4.38 (P < 0.0001)

Comorbidity: Chronic respiratory diseases

| Study | Non survivors | Survivors | Total | Weight | Odds Ratio | M-H, Random, 95% CI |
|-------|---------------|-----------|-------|--------|------------|-------------------|
| Cao (9) | 4 | 17 | 6 | 85 | 19.0% | 4.05 [1.00, 16.34] |
| Chen (10) | 0 | 19 | 0 | 36 | Not estimable | |
| Chen (9) | 11 | 113 | 7 | 161 | 25.1% | 2.37 [0.89, 6.32] |
| Deng (19) | 22 | 109 | 3 | 116 | 21.1% | 9.52 [2.76, 32.86] |
| Du (11) | 0 | 21 | 0 | 159 | Not estimable | |
| Li (12) | 0 | 5 | 0 | 20 | Not estimable | |
| Tang (13) | 0 | 21 | 0 | 162 | Not estimable | |
| Wang (14) | 0 | 65 | 0 | 274 | Not estimable | |
| Yan (15) | 3 | 108 | 2 | 85 | 14.2% | 1.19 [0.19, 7.26] |
| Yang (16) | 2 | 32 | 0 | 20 | 6.6% | 3.36 [0.15, 73.68] |
| Yuan (17) | 0 | 10 | 3 | 17 | 6.6% | 0.20 [0.01, 4.24] |
| Zhou (18) | 8 | 54 | 0 | 137 | 7.3% | 36.86 [2.04, 686.48] |

Total (95% CI) | 48 | 21 | 100.0% | 3.38 [1.41, 8.11] |

Heterogeneity: Tau² = 0.54; Ch² = 10.52, df = 6 (P = 0.10); I² = 43%
Test for overall effect: Z = 2.73 (P = 0.006)

Figure 2. Continued
Comorbidity: Cerebrovascular diseases

Mean difference in heart rate at admission, beats/minute

Elevated creatine kinase as a predictor of mortality

Figure 2. Continued
Elevated LDH as a predictor of mortality

| Study or Subgroup | Non survivors | Survivors | Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|---------------|-----------|-------|--------|--------------------------------|--------------------------------|
| Cao (8)           | 0             | 17        | 85    |        | Not estimable                  |                                |
| Chen (10)         | 13            | 19        | 36    |        | 34.3% 1.38 [0.43, 4.47]        |                                |
| Chen (9)          | 93            | 113       | 206   |        | 38.6% 27.90 [14.50, 53.68]     |                                |
| Deng (19)         | 0             | 0         | 0     |        | Not estimable                  |                                |
| Du (11)           | 0             | 21        | 15    |        | Not estimable                  |                                |
| Li (12)           | 0             | 5         | 5     |        | Not estimable                  |                                |
| Tang (13)         | 0             | 21        | 21    |        | Not estimable                  |                                |
| Wang (14)         | 0             | 65        | 65    |        | Not estimable                  |                                |
| Yan (15)          | 0             | 108       | 108   |        | Not estimable                  |                                |
| Yang (16)         | 0             | 32        | 32    |        | Not estimable                  |                                |
| Yuan (17)         | 0             | 10        | 10    |        | Not estimable                  |                                |
| Zhou (18)         | 53            | 54        | 107   |        | 50.73 [8.62, 377.29]           |                                |

Total (95% CI) 574 1271 100.0% 11.82 [1.32, 105.82]

Heterogeneity: Tau² = 3.29; Chi² = 20.58, df = 2 (P = 0.0001); I² = 90%
Test for overall effect: Z = 2.21 (P = 0.03)

Elevated cardiac troponin I (CTnI) as a predictor of mortality

| Study or Subgroup | Non survivors | Survivors | Total | Weight | Odds Ratio M-H, Random, 95% CI | Odds Ratio M-H, Random, 95% CI |
|-------------------|---------------|-----------|-------|--------|--------------------------------|--------------------------------|
| Cao (8)           | 6             | 17        | 23    |        | 14.0% 96.65 [5.10, 1931.14]    |                                |
| Chen (10)         | 0             | 19        | 19    |        | Not estimable                  |                                |
| Chen (9)          | 68            | 113       | 181   |        | 49.2% 14.71 [7.87, 28.21]      |                                |
| Deng (19)         | 0             | 109       | 109   |        | Not estimable                  |                                |
| Du (11)           | 0             | 21        | 21    |        | Not estimable                  |                                |
| Li (12)           | 1             | 5         | 6     |        | 13.8% 4.75 [0.24, 92.97]       |                                |
| Tang (13)         | 0             | 21        | 21    |        | Not estimable                  |                                |
| Wang (14)         | 0             | 85        | 85    |        | Not estimable                  |                                |
| Yan (15)          | 0             | 108       | 108   |        | Not estimable                  |                                |
| Yang (16)         | 0             | 32        | 32    |        | Not estimable                  |                                |
| Yuan (17)         | 0             | 10        | 10    |        | Not estimable                  |                                |
| Zhou (18)         | 23            | 54        | 77    |        | 23.0% 100.90 [3.12, 775.83]    |                                |

Total (95% CI) 574 1271 100.0% 25.51 [7.17, 90.75]

Heterogeneity: Tau² = 0.74; Chi² = 6.36, df = 3 (P = 0.15); I² = 44%
Test for overall effect: Z = 5.00 (P = 0.000001)

Elevated brain natriuretic peptide (BNP) or proBNP as a predictor of mortality

| Study or Subgroup | Nonsurvivors | Survivors | Total | Mean | SD | Mean | SD | Total | Weight | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|--------------|-----------|-------|------|----|------|----|-------|--------|----------------------------------|----------------------------------|
| Cao (8)           | 46.3         | 51.67     | 17    | 0    | 0  | 0    | 0  | 95    |         | Not estimable                     |                                  |
| Chen (10)         | 0            | 19        | 0     | 0    | 0  | 0    | 0  | 36    |         | Not estimable                     |                                  |
| Chen (9)          | 80.0         | 356.92    | 113   | 72   | 41.25 | 161 | 95.9% | 728.00 [661.88, 794.12]          |                                  |
| Deng (19)         | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 116   |         | Not estimable                     |                                  |
| Du (11)           | 970          | 727.62    | 21    | 390  | 265.12 | 158 | 4.2% | 580.00 [206.06, 939.94]          |                                  |
| Li (12)           | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 162   |         | Not estimable                     |                                  |
| Tang (13)         | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 274   |         | Not estimable                     |                                  |
| Wang (14)         | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 20    |         | Not estimable                     |                                  |
| Yan (15)          | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 85    |         | Not estimable                     |                                  |
| Yang (16)         | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 20    |         | Not estimable                     |                                  |
| Yuan (17)         | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 17    |         | Not estimable                     |                                  |
| Zhou (18)         | 0            | 0         | 0     | 0    | 0  | 0    | 0  | 137   |         | Not estimable                     |                                  |

Total (95% CI) 574 1271 100.0% 721.71 [657.02, 786.41]

Heterogeneity: Tau² = 0.00; Chi² = 0.82, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 21.86 (P < 0.000001)

Figure 2. Continued
### Development of shock as a predictor of mortality

| Study or Subgroup | Non survivors Events | Survivors Events | Total | Total Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|----------------------|------------------|-------|-------------|--------------------------------|
| Cao (6)           | 7                    | 17               | 3     | 95          | 22.4%                          |
| Chen (10)         | 0                    | 19               | 0     | 36          | Not estimable                  |
| Chen (9)          | 46                   | 113              | 0     | 161         | 18.5%                          |
| Deng (19)         | 13                   | 109              | 0     | 116         | 18.4%                          |
| Du (11)           | 0                    | 21               | 0     | 158         | Not estimable                  |
| Li (12)           | 0                    | 5                | 0     | 20          | Not estimable                  |
| Tang (13)         | 0                    | 21               | 0     | 192         | Not estimable                  |
| Wang (14)         | 3                    | 65               | 5     | 274         | 22.6%                          |
| Yan (15)          | 0                    | 108              | 0     | 85          | Not estimable                  |
| Yang (19)         | 0                    | 32               | 0     | 20          | Not estimable                  |
| Yuan (17)         | 0                    | 10               | 0     | 17          | Not estimable                  |
| Zhou (18)         | 59                   | 54               | 0     | 137         | 18.1%                          |

Total (95% CI): 574 / 1271 / 100.0%

Heterogeneity: $\tau^2 = 6.27$; $\chi^2 = 26.14$, df = 4 ($P < 0.0001$); $I^2 = 95$

Test for overall effect: $Z = 3.20$ ($P = 0.001$)

### Development of arrhythmia as a predictor of mortality

| Study or Subgroup | Non survivors Events | Survivors Events | Total | Total Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|----------------------|------------------|-------|-------------|--------------------------------|
| Cao (8)           | 12                   | 17               | 6     | 85          | 35.5%                          |
| Chen (10)         | 0                    | 19               | 0     | 36          | Not estimable                  |
| Chen (9)          | 0                    | 113              | 0     | 161         | Not estimable                  |
| Deng (19)         | 0                    | 109              | 0     | 116         | Not estimable                  |
| Du (11)           | 0                    | 21               | 0     | 158         | Not estimable                  |
| Li (12)           | 0                    | 5                | 0     | 20          | Not estimable                  |
| Tang (13)         | 0                    | 21               | 0     | 162         | Not estimable                  |
| Wang (14)         | 13                   | 65               | 22    | 274         | 38.1%                          |
| Yan (15)          | 0                    | 108              | 0     | 85          | Not estimable                  |
| Yang (19)         | 0                    | 32               | 0     | 20          | Not estimable                  |
| Yuan (17)         | 0                    | 10               | 0     | 17          | Not estimable                  |
| Zhou (18)         | 27                   | 54               | 0     | 137         | 26.4%                          |

Total (95% CI): 574 / 1271 / 100.0%

Heterogeneity: $\tau^2 = 4.25$; $\chi^2 = 19.17$, df = 4 ($P < 0.0001$); $I^2 = 90$

Test for overall effect: $Z = 2.40$ ($P = 0.02$)

### Development of acute myocardial injury as a predictor of mortality

| Study or Subgroup | Non survivors Events | Survivors Events | Total | Total Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|----------------------|------------------|-------|-------------|--------------------------------|
| Cao (8)           | 12                   | 17               | 3     | 85          | 18.3%                          |
| Chen (10)         | 0                    | 19               | 0     | 36          | Not estimable                  |
| Chen (9)          | 72                   | 113              | 18    | 161         | 30.4%                          |
| Deng (19)         | 65                   | 109              | 1     | 116         | 13.9%                          |
| Du (11)           | 0                    | 21               | 0     | 158         | Not estimable                  |
| Li (12)           | 0                    | 5                | 0     | 20          | Not estimable                  |
| Tang (13)         | 0                    | 21               | 0     | 162         | Not estimable                  |
| Wang (14)         | 39                   | 65               | 31    | 274         | 30.4%                          |
| Yan (15)          | 0                    | 108              | 0     | 85          | Not estimable                  |
| Yang (19)         | 0                    | 32               | 0     | 20          | Not estimable                  |
| Yuan (17)         | 0                    | 10               | 0     | 17          | Not estimable                  |
| Zhou (18)         | 0                    | 54               | 1     | 137         | 7.1%                           |

Total (95% CI): 574 / 1271 / 100.0%

Heterogeneity: $\tau^2 = 0.69$; $\chi^2 = 13.71$, df = 4 ($P = 0.009$); $I^2 = 71$

Test for overall effect: $Z = 6.13$ ($P < 0.00001$)

Figure 2. Continued
Development of acute heart failure as a predictor of mortality

| Study or Subgroup | Non survivors Events | Survivors Events | Total | Weight | Odds Ratio M-H, Random, 95% CI |
|-------------------|----------------------|----------------|-------|--------|-------------------------------|
| Cao (8)           | 0                    | 17             | 0     | 85     | Not estimable                 |
| Chen (10)         | 0                    | 19             | 0     | 38     | Not estimable                 |
| Chen (9)          | 41                   | 113            | 3     | 161    | 36.2% 29.99 [8.99, 100.06]     |
| Deng (19)         | 0                    | 109            | 0     | 118    | Not estimable                 |
| Du (11)           | 0                    | 21             | 0     | 159    | Not estimable                 |
| Li (12)           | 0                    | 5              | 0     | 20     | Not estimable                 |
| Tang (13)         | 0                    | 21             | 0     | 162    | Not estimable                 |
| Wang (14)         | 25                   | 65             | 33    | 274    | 39.2% 4.56 [2.46, 8.47]        |
| Yan (15)          | 0                    | 108            | 0     | 85     | Not estimable                 |
| Yang (16)         | 0                    | 32             | 0     | 20     | Not estimable                 |
| Yuan (17)         | 0                    | 10             | 0     | 17     | Not estimable                 |
| Zhou (18)         | 0                    | 54             | 16    | 137    | 24.6% 0.07 [0.00, 1.15]        |
| Total (95% CI)    | 574                  | 1271           | 56    | 100.0% | 3.21 [0.34, 30.10]            |
| Heterogeneity Tau² | 3.23                 | Ch² P = 18.02  | df = 2 | P = 0.0001; P = 0.09           |
| Test for overall effect Z | 1.02 (P = 0.31)         |

Figure 2. Continued

Discussion

Our meta-analysis of comparative studies in hospitalized patients with COVID-19 shows that patients who died had a significant involvement of cardiovascular system. Non-survivors had preponderance of cardiovascular disease risk factors - male gender, older than 50 years, a history of dyslipidemia, smoking, hypertension, and diabetes. They also had a significant past history of a preexisting cardiovascular condition, including chronic heart failure and cerebrovascular accident. At presentation, they had a high prevalence of hypoxemia, higher heart rate, dyspnea, and fatigue suggesting cardiovascular system instability. While in the hospital, non-survives had a significant increase in serum level of laboratory biomarkers such as cardiac troponin I, LDH, BNP or proBNP, and CK, suggesting new myocardial injury or worsening of a pre-existing heart disease. Not surprisingly, non-survivors had clinical evidence of cardiovascular system instability as manifested by the presence of shock, cardiac arrhythmias, and acute respiratory distress.

In a large series of hospitalized patients with COVID-19 in New York City, Lala et al. showed that elevated troponin I level was significantly associated with coronary artery diseases, atrial fibrillation, and heart failure. These authors suggested a 3-fold increase in the mortality rate with troponin-I elevation to 3-times above the upper reference limit.

In an attempt to develop a risk prediction model, Liang et al. used the retrospective data of the National Health Commission of China to identify independent predictors of mortality in COVID-19 patients. The validated results showed that an abnormality on chest radiography, older age, hemoptysis, dyspnea, unconsciousness, number of comorbidities, a history of cancer, neutrophil-to-lymphocyte ratio, LDH, and direct bilirubin remained independent predictors of death.

Chen et al. compared cardiovascular system variables in a small number of severely sick (39 cases) and critically sick (15 cases) COVID-19 patients, and found that diabetes, significant leukocytosis, elevated level of inflammatory elements (interleukin-6, C-reactive protein, erythrocyte sedimentation rate, D-dimer, and procalcitonin), elevated markers of myocardial injury (CK-MB, troponin-I, myoglobin, and proBNP), hypotension and tachycardia at admission, atrioventricular block, pericardial effusion, and right heart block were more prevalent in critically-ill patients.

Our study showed that cardiovascular disease risk factors, its manifestations, and related laboratory biomarkers were powerful predictors of death in COVID-19 patients. Our meta-analysis including several large and small studies confirmed the hypothesis that cardiovascular system instability predicts mortality in COVID-19 patients. Unfortunately, the included studies did not provide sufficient data on the type of cardiac arrhythmia. Also, due to the limited number of events for each subgroup analysis, some variables did not reach a statistical significance of which an acute heart failure is a major one. Although studying the efficacy of various therapeutic modalities was beyond the scope of our meta-analysis, non-survivors had a tendency to receive more aggressive treatment such as mechanical ventilation and corticosteroid administration. However, none of these therapeutic modalities seemed to improve the survival in patients with COVID-19.

In conclusion, this meta-analysis of comparative studies highlights the pivotal role of cardiovascular system instability in predicting mortality in patients with COVID-19. A careful consideration of history of cardiovascular disease and its risk factors, attention to signs and symptoms at presentation and during hospitalization, and related laboratory parameters should alert the clinicians toward the high-risk patient.
Figure 3. Forest plots demonstrating the effect of major therapeutic options given to the patients with COVID-19. The meta-analysis estimated odds ratio and 95% confidence interval for 4 major treatment modalities. Mantel-Haenszel statistical method using a random-effects model was utilized for all analyses.
Mechanical ventilation in non-survivors and survivors.

| Study or Subgroup | Non-survivors | Survivors | Total | Weight | Odds Ratio | M-H, Random, 95% CI |
|-------------------|--------------|-----------|-------|--------|------------|---------------------|
| Cao (8)           | 0            | 17        | 0     | 85     | Not estimable |                     |
| Chen (10)         | 13           | 19        | 11    | 36     | 22.7%       | 4.92 [1.48, 16.34]   |
| Chen (8)          | 93           | 113       | 26    | 161    | 24.3%       | 24.14 [1.27, 45.79]  |
| Deng (10)         | 0            | 19        | 0     | 116    | Not estimable |                     |
| Du (13)           | 21           | 21        | 1     | 158    | 14.2%       | 4515.00 [178.21, 114386.13] |
| Li (12)           | 0            | 5         | 0     | 20     | Not estimable |                     |
| Tang (13)         | 0            | 21        | 0     | 162    | Not estimable |                     |
| Wang (14)         | 105          | 85        | 0     | 274    | Not estimable |                     |
| Yang (15)         | 30           | 108       | 5     | 85     | 23.4%       | 6.15 [2.27, 16.67]   |
| Yuan (17)         | 0            | 32        | 7     | 20     | 15.4%       | 0.03 [0.00, 0.52]    |
| Zhou (18)         | 0            | 54        | 0     | 137    | Not estimable |                     |

Total (95% CI) | 574 | 1271 | 100.0% | 9.07 [1.42, 58.18] |

Heterogeneity: Tau²=3.59; Chi²=40.39; df=4 (P=0.00001); I²=90%
Test for overall effect: Z=2.33 (P=0.02)

Figure 3. Continued

Conflict of Interests Statement

All authors have no conflict of interests to disclose.

1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069.

2. Nie SF, Yu M, Xie T, Yang F, Wang HB, Wang ZH, Li M, Gao XL, Lv 6. Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. Evaluation of cardiac troponin i is an independent predictor for mortality in hospitalized patients with coronavirus disease 2019. Circulation 2020;142:608–610.

3. Angeli F, Spangelo A, De Ponti R, Visca D, Marazzato J, Palmiotto G, Feci D, Rebaldi G, Fabbri LM, Verdecchia P. Electrocardiographic features of patients with COVID-19 pneumonia. Eur J Intern Med 2020;78:101–106.

4. Chen Q, Xu L, Dai Y, Ling Y, Mao J, Qian J, Zhu W, Di W, Ge J. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol 2020;43:796–802.

5. Lala A, Johnson KW, Januzzi JL, Russak AJ, Paranjpe I, Richter BJ, Wang SJ, Zhang XB, He SL, Qiu ZH, Liao YH, Zhou ZH, Cheng X. Cardiac troponin i is an independent predictor for mortality in hospitalized patients with coronavirus disease 2019. Circulation 2020;142:608–610.

6. Panic N, Leoncini E, De Belvis G, Ricciardi W, Boccia S. Evaluation of the endorse the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One 2013;8:e83138.

7. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008–2012.

8. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, Liu Q. Clinical features and short-term outcomes of 102 patients with Coronavirus disease 2019 in Wuhan. China. Clin Infect Dis 2020;71:748–753.

9. Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, Chen X, Luo M, Liang K, Gao S, Zhang Y, Deng L, Xiong Y. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci 2020;glaa089. https://doi.org/10.1093/gerona/glaa089. Online ahead of print.

10. Liu RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, Gao FY, Du J, Zheng CL, Zhu Q, Hu M, Li XY, Peng P, Shi HZ. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020;55.

11. Li YK, Peng S, Li LQ, Wang Q, Peng W, Zhang N, Fu XN. Clinical and transmission characteristics of Covid-19 - a retrospective study of 25 cases from a single thoracic surgery department. Curr Med Sci 2020;40:295–300.

12. Yang X, Yu Y, Xu J, Hu D, Bao M, Liu H, Zhou J, Jiang H. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;81:639–645.

13. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, Yu X, Dong K. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care 2020:8.

14. Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang H. Coronavirus disease 2019 in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475–481.

15. Yuan M, Yin W, Tao Z, Tan W, Hu Y. Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China. PLoS One 2020;15:e0230548.

16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.

17. Beng L, Liu W, Liu K, Fang YY, Shang J, Zhou L, Wang K, Leng F, Wei S, Chen L, Liu HG. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl) 2020;133:1261–1267.

18. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, Li Y, Gwan W, Sang L, Lu J, Xu Y, Chen G, Guo H, Guo J, Chen Z, Zhao Y, Li S, Zhang N, Zhong N, He J. China Medical Treatment Expert Group for C. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020;180:1–9.